the Efficacy of Ivermectin Alone or With Microneedling in Treatment of Cutaneous Warts.

ConditionWarts

Trial statusNot yet recruiting

Trial phaseEarly Phase 1

Trial typeInterventional

Biological sexAll

Age11-80

SponsorAssiut University

About this trial

To compare between the efficacy and safety of topical ivermectin alone, microneedling with topical ivermectin and topical salicylic acid in treatment of cutaneous warts.

topical ivermectin 1% will be applied on warts whole night clinical assessment will be done every 2 weeks

Microneedling will be performed on the lesion using a microneedling pen type device with a 1-cm tip diameter at a 2-mm depth setting for 2-3 minutes until pinpoint bleebing occurs 1 mL of topical ivermectin 1% will be applied on to the wart tissue.

Sessions: Sessions will be performed every 2 weeks until complete cure or for maximum 6 sessions (total 3 month)

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

patients with cutaneous non genital warts aged 11:80 y.

No concurrent systemic or topical treatment of warts

Disqualifiers

Genital warts.

Pregnancy and lactation.

History of any bleeding, clotting disorder or using anticoagulants

Chronic systemic diseases such as chronic renal failure, hepaticinsufficiency, and cardiovascular disorders.

Trial design

Design model

Parallel

Treatments tested in this trial

Ivermectin
Drug
patients with non-genital cutaneous warts will be treated by topical application of ivermectin : topical ivermectin 1% will be applied under occlusion overnight daily then revaluated every 2 weeks for maximum 12 weeks
microneedling
Device
patients with non-genital cutaneous warts will be treated by microneedling (2mm depth) every 2-weeks until complete clearance or for a maximum of 12weeks
Salicylic Acid
Drug
patients with non-genital cutaneous warts will be treated by topical application of ivermectin : cotton soaked with topical salicylic acid will be applied under occlusion overnight daily then revaluated every 2 weeks for maximum 12 weeks

Treatment groups

88 Participants

are divided into 4 treatment groups

Group A: topical ivermectinExperimental treatment 1 intervention

Group B: microneedlingExperimental treatment 1 intervention

Group C: microneedling with ivermectinExperimental treatment 2 interventions

Group D: topical salicylic acidActive comparator 1 intervention

Trial outcomes

Primary outcomes

evaluation of the efficacy of topical ivermectin in treatment of cutaneous warts.

clinical assessment of warts at the baseline \& each visit comparing photographs at different timeline .

Time frame

baseline

Secondary outcomes

evaluation of the efficacy of topical ivermectin combined with microneedling in treatment of cutaneous warts.

clinical assessment of warts at the baseline \& at each visit every 2 weeks

Time frame

baseline

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Assiut University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: